hepatocellular carcinoma
Conditions
Interventions
Interferon treatment group:none
Control group:none
Sponsors
Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with HBV-related HCC who underwent radical resection and met the following criteria would be recruited as study subjects in this project. 1. 18 years old 6 months; 4. Hepatocellular carcinoma confirmed by histopathological examination; 5. The tumor was evaluated as CNLC stage I before operation and received radical resection or radiofrequency ablation; 6. normal or well compensated liver function, Child-Pugh grade A; 7. sign informed consent and be able to comply with the requirements of the protocol; If the patient was unable to provide written informed consent, the patient's legal guardian or representative was required to do so.
Exclusion criteria
Exclusion criteria: 1. Patients had received any other systemic therapy against liver cancer before surgery, such as liver transplantation, chemoembolization, radiotherapy, chemotherapy, molecular targeted therapy, and biological therapy; 2. patients receiving hepatotoxic drugs or immunosuppressive agents or postoperative adjuvant chemotherapy 3. previous or concurrent with other malignant tumors; 4. patients who had received previous interferon therapy; 5. allergic to interferon and its components; 6. co-infection with HAV, HCV, HDV, HEV, HIV, alcoholic liver disease, inherited metabolic liver disease, drug-induced liver disease and other chronic liver diseases; 7. combined with autoimmune diseases, including autoimmune liver disease, psoriasis, etc; 8. severe liver dysfunction or decompensated cirrhosis; 9. creatinine higher than 1.5 times the upper limit of normal; 10. patients with serious diseases of heart, lung, kidney, brain, blood and other important organs; 11. patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.); 12. unstable diabetes, hypertension, thyroid disease, etc; 13. patients with history of severe retinopathy or other evidence of retinopathy; 14. drug abuse or alcohol abuse; 15 .pregnant or lactating women, or patients who plan to have children during the study period and do not want to use contraception; 16. The investigator considered that the subject was not suitable for the study; 17. patients participating in other clinical trials at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year recurrence-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival at 2 years after surgery;HBV DNA response rate;HBsAg clearance rate; | — |
Countries
China
Contacts
Public ContactZhishuo Mo
Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed